Bimekizumab

Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.

The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat). Injection site reactions were also common, reported in 3% of subjects.

Bimekizumab was approved for medical use in the European Union in August 2021, and in the United States in October 2023.

Medical uses
In the EU, bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.

History
Bimekizumab is being developed by Belgian pharmaceutical company UCB.

Names
Bimekizumab is the international nonproprietary name (INN).

Research
Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab but also secukinumab and ustekinumab for the treatment of plaque psoriasis.